4.7 Article

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 15, Pages 8608-8633

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00955

Keywords

-

Funding

  1. CHDI Foundation

Ask authors/readers for more resources

Mutant huntingtin (mHTT) protein carrying the elongated N-terminal polyglutamine (polyQ) tract misfolds and forms protein aggregates characteristic of Huntington's disease (HD) pathology. A high-affinity ligand specific for mHTT aggregates could serve as a positron emission tomography (PET) imaging biomarker for HD therapeutic development and disease progression. To identify such compounds with binding affinity for polyQ aggregates, we embarked on systematic structural activity studies; lead optimization of aggregate-binding affinity, unbound fractions in brain, permeability, and low efflux culminated in the discovery of compound 1, which exhibited target engagement in autoradiography (ARG) studies in brain slices from HD mouse models and postmortem human HD samples. PET imaging studies with C-11-labeled 1 in both HD mice and WT nonhuman primates (NHPs) demonstrated that the right-hand-side labeled ligand [C-11]-1R (CHDI-180R) is a suitable PET tracer for imaging of mHTT aggregates. [C-11]-1R is now being advanced to human trials as a first-in-class HD PET radiotracer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available